Literature DB >> 29713005

Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative.

Fernanda Rodrigues-Soares1,2, Fernanda S G Kehdy1,3, Julia Sampaio-Coelho1, Poliana X C Andrade1, Carolina Céspedes-Garro4, Camila Zolini1,5, Marla M Aquino1, Mauricio L Barreto6,7, Bernardo L Horta8, Maria Fernanda Lima-Costa9, Alexandre C Pereira10, Adrián LLerena11,12, Eduardo Tarazona-Santos13.   

Abstract

We present allele frequencies involving 39 pharmacogenetic biomarkers studied in Brazil, and their distribution on self-reported race/color categories that: (1) involve a mix of perceptions about ancestry, morphological traits, and cultural/identity issues, being social constructs pervasively used in Brazilian society and medical studies; (2) are associated with disparities in access to health services, as well as in their representation in genetic studies, and (3), as we report here, explain a larger portion of the variance of pharmaco-allele frequencies than geography. We integrated a systematic review of studies on healthy volunteers (years 1968-2017) and the analysis of allele frequencies on three population-based cohorts from northeast, southeast, and south, the most populated regions of Brazil. Cross-validation of results from these both approaches suggest that, despite methodological heterogeneity of the 120 studies conducted on 51,747 healthy volunteers, allele frequencies estimates from systematic review are reliable. We report differences in allele frequencies between color categories that persist despite the homogenizing effect of >500 years of admixture. Among clinically relevant variants: CYP2C9*2 (null), CYP3A5*3 (defective), SLCO1B1-rs4149056(C), and VKORC1-rs9923231(A) are more frequent in Whites than in Blacks. Brazilian Native Americans show lower frequencies of CYP2C9*2, CYP2C19*17 (increased activity), and higher of SLCO1B1-rs4149056(C) than other Brazilian populations. We present the most current and informative database of pharmaco-allele frequencies in Brazilian healthy volunteers.

Entities:  

Mesh:

Year:  2018        PMID: 29713005     DOI: 10.1038/s41397-018-0015-7

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  5 in total

1.  Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Authors:  Vera Kim; Thijs van der Wal; Miriam Yumie Nishi; Luciana Ribeiro Montenegro; Flair Jose Carrilho; Yujin Hoshida; Suzane Kioko Ono
Journal:  Pharmacogenomics       Date:  2020-06-03       Impact factor: 2.533

Review 2.  Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.

Authors:  Carolina Dagli-Hernandez; Yitian Zhou; Volker Martin Lauschke; Fabiana Dalla Vecchia Genvigir; Thiago Dominguez Crespo Hirata; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmacol Rep       Date:  2021-08-17       Impact factor: 3.024

3.  Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications.

Authors:  Frederick Zhang; Joseph Finkelstein
Journal:  Pharmgenomics Pers Med       Date:  2019-07-02

4.  Genetic Variants in PTGS1 and NOS3 Genes Increase the Risk of Upper Gastrointestinal Bleeding: A Case-Control Study.

Authors:  Marcela Forgerini; Gustavo Urbano; Tales Rubens de Nadai; Sabrina Setembre Batah; Alexandre Todorovic Fabro; Patrícia de Carvalho Mastroianni
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

Review 5.  Applying an equity lens to pharmacogenetic research and translation to under-represented populations.

Authors:  Tiana Luczak; David Stenehjem; Jacob Brown
Journal:  Clin Transl Sci       Date:  2021-07-30       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.